Merck & Co Inc (MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

• Relazione annuale (10-K)

  Una panoramica annuale del business, dei risultati finanziari e dei rischi dell'azienda.

  Depositato il 2026-02-24

  Vedi documento

• Relazione trimestrale (10-Q)

  Un aggiornamento sull'andamento finanziario degli ultimi tre mesi.

  Depositato il 2026-08-07

  Vedi documento

• Comunicazione price-sensitive (8-K)

  Una comunicazione su un evento importante, come un cambio ai vertici o un grande annuncio.

  Depositato il 2026-08-04

  Vedi documento

• 4d agoPOSITIVE
  Merck, accordo di licenza da oltre 2 miliardi di dollari con SciBrunch Therapeutics

  Merck has entered into a licensing agreement with SciBrunch Therapeutics for a potential oncology treatment. The deal could be worth over $2 billion, signaling Merck's strategic investment in expanding its cancer drug pipeline. This move aims to bolster Merck's position in the competitive oncology market by acquiring promising early-stage assets. Investors will be watching the clinical development closely, as successful progression could lead to significant future revenue streams and enhance Merck's long-term growth prospects.

• 8/20/2026POSITIVE
  Moderna limita i rialzi, ma le azioni Merck restano da comprare

  Merck & Co. (MRK) shares are positioned for a rally to $179 in the coming months, according to Morgan Stanley analyst Terence Flynn. This optimism stems from the strong performance of a combination therapy involving Merck's Keytruda and Moderna's (MRNA) experimental cancer drug in a late-stage trial. The trial demonstrated efficacy in high-risk melanoma patients, a significant breakthrough. Morgan Stanley's bullish stance, reiterated in a research note dated August 20th, highlights the potential for Merck's stock to continue its upward trajectory, building on recent positive developments in its oncology pipeline.

• 8/19/2026POSITIVE
  Merck, Moderna Melanoma Vaccine Study Succeeds

  Merck and Moderna have reported encouraging outcomes from a Phase 3 trial for their collaborative personalized mRNA melanoma vaccine. The study demonstrated a substantial reduction in the recurrence rate of melanoma, the most aggressive skin cancer. This success in a late-stage trial suggests a promising new therapeutic avenue for Merck, potentially bolstering its oncology pipeline and future revenue streams. Investors will be watching for regulatory filings and potential market launch timelines, which could significantly impact the company's valuation.

• 5/18/2026NEUTRAL
  Merck Eyes $6 Billion in Seven-Part Bond Sale for Terns Deal

  Merck & Co. is planning a significant debt offering, aiming to raise approximately $6 billion through a seven-part bond sale. This move is primarily intended to fund its acquisition of Terns Pharmaceuticals Inc. The bond sale is structured for investment-grade investors, indicating Merck's strong credit profile. While the acquisition itself may signal strategic growth, the bond issuance represents a financing activity that does not inherently boost or detract from the company's immediate stock value, thus maintaining a neutral short-term outlook for investors.

• 4/21/2026NEGATIVE
  Perché il titolo Merck sta scendendo martedì?

  Il titolo di Merck & Co., Inc. ha subito un significativo ribasso martedì, a seguito dell'annuncio che il suo studio di Fase 3 LITESPARK-012 per il carcinoma renale avanzato non ha raggiunto gli endpoint primari. Questo fallimento dello studio clinico rappresenta una battuta d'arresto importante per la pipeline oncologica dell'azienda e per le proiezioni di ricavi futuri. Gli investitori stanno reagendo negativamente alla notizia, poiché il candidato farmaco era considerato un motore di crescita chiave. La mancanza di risultati positivi dello studio porterà probabilmente a revisioni al ribasso delle stime sugli utili e potrebbe influire sulla valutazione del titolo.

• 4/7/2026NEGATIVE
  Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

  Merck & Co. has lowered its offer price for Terns Pharmaceuticals following a review of TERN-701 trial data. While Merck maintains its strategic interest in Terns, particularly concerning its potential in Chronic Myeloid Leukemia (CML) treatments and amid ongoing competition, the price adjustment signals a potential recalibration of the deal's valuation based on new clinical insights. Investors will monitor how this revised offer impacts the finalization of the acquisition and Merck's competitive positioning in the oncology space.

• 4/1/2026POSITIVE
  Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

  Merck has entered into a strategic alliance with Infinimmune to leverage the latter's Anthrobody platform for the development of next-generation antibody drugs. This collaboration aims to harness human-derived antibodies, potentially leading to more effective and targeted therapeutics. The partnership signifies Merck's commitment to innovation in its biologics pipeline and its pursuit of novel drug discovery technologies. Investors will be watching for clinical trial progress and the potential for breakthrough treatments stemming from this alliance.

• 3/25/2026POSITIVE
  Merck to Buy Terns for $6.7B to Grow in Blood Cancers

  Merck & Co. has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion. This strategic move aims to bolster Merck's oncology portfolio by integrating Terns' promising leukemia treatment pipeline. The acquisition is particularly significant as Merck faces the upcoming patent expiration of its top-selling cancer drug, Keytruda. Investors will be watching how this integration impacts Merck's future revenue streams and its competitive position in the lucrative blood cancer market.